GLP-1 receptor agonists and bariatric surgery may have differing effects on cardiovascular remodeling, hypothesized to be due to GLP-1 agonist blood concentrations being three times higher.
Do GLP-1 receptor agonists and bariatric surgery have different effects on cardiovascular morbidity, mortality, and cardiac remodeling?
This review highlights potential differences in cardiovascular remodeling effects between pharmacological GLP-1 receptor agonists and physiological GLP-1 increases following bariatric surgery.
Obesity and associated comorbidities reach epidemic proportions nowadays. Several treatment strategies exist, but bariatric surgery has the only longstanding effects. Since a few years, there is increasing interest in the effects of gastro-intestinal hormones, in particular Glucagon-Like Peptide-1 (GLP-1) on the remission of Type 2 Diabetes (T2DM) and its effects on cardiac cardiovascular morbidity, cardiac remodeling, and mortality. In the past years several high quality multicenter randomized controlled trials were developed to assess the effects of GLP-1 receptor agonist therapy on cardiovascular morbidity and mortality. Most of the trials were designed and powered as non-inferiority trials to demonstrate cardiovascular safety. Most of these trials show a reduction in cardiovascular morbidity in patients with T2DM. Some follow-up studies indicate potential beneficial effects of GLP-1 receptor agonists on cardiovascular function in patients with heart failure, however the results are contradictory, and we need long-term studies to make firm conclusions about the pleiotropic properties of incretin-based therapies. However, it seems that GLP-1 receptor agonists have different effects than the increased GLP-1 production after bariatric surgery on cardiovascular remodeling. One of the hypotheses is that the blood concentrations of GLP-1 receptor agonists are three times higher compared to GLP-1 increase after bariatric and metabolic surgery. The purpose of this narrative review is to summarize the effects of GLP-1 on cardiovascular morbidity, mortality and remodeling due to medication but also due to bariatric and metabolic surgery. The second objective is to explain the possible differences in effects of GLP-1 agonists and bariatric and metabolic surgery.
Timmermans et al. (Tue,) conducted a review in Obesity and Type 2 Diabetes. GLP-1 receptor agonists and bariatric surgery was evaluated. GLP-1 receptor agonists and bariatric surgery may have differing effects on cardiovascular remodeling, hypothesized to be due to GLP-1 agonist blood concentrations being three times higher.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: